Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Qinhong Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0654-5290; OpenAlex author ID A5086446483. Sources: OpenAlex.

Their work

Papers
42 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
64
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 6 papers · 2014: 6 papers · 2015: 8 papers · 2016: 4 papers · 2017: 3 papers · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers

Papers 42

  1. Identification and validation of a hypoxia- and immune-related prognostic signature for pancreatic cancer. Last author DOI 10.1016/j.bbrep.2025.102205↗
  2. Targeting IRF7 to overcome gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.114207↗
  3. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Last author DOI 10.1177/0963689720929987↗
  4. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01038↗
  5. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pa… First author DOI 10.1371/journal.pone.0216603↗
  6. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  7. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Last author DOI 10.3892/ijo.2018.4604↗
  8. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Co-author DOI 10.1016/j.csbj.2018.10.006↗
  9. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  10. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  11. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  12. Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells. First author DOI 10.1158/1541-7786.mcr-17-0023↗
  13. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  14. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Co-author DOI 10.1155/2016/3897250↗
  15. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer. Co-author DOI 10.1155/2016/6815727↗
  16. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  17. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Co-author DOI 10.18632/oncotarget.7776↗
  18. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Co-author DOI 10.1080/15384047.2015.1040952↗
  19. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  20. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  21. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  22. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  23. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗
  24. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.5045↗
  25. Superoxide dismutase promotes the epithelial-mesenchymal transition of pancreatic cancer cells via activation of the H2O2/ERK/NF-κB axis. Co-author DOI 10.3892/ijo.2015.2938↗
  26. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Co-author DOI 10.1016/j.canlet.2014.02.003↗
  27. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. First author DOI 10.1016/j.febslet.2014.01.007↗
  28. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Co-author DOI 10.1155/2014/546353↗
  29. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-3426↗
  30. Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer. Co-author DOI 10.2174/1568009614666140331231658↗
  31. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗
  32. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Co-author DOI 10.1158/1535-7163.mct-12-0809↗
  33. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0609↗
  34. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Co-author DOI 10.1186/1476-4598-12-66↗
  35. Aspirin: a potential therapeutic approach in pancreatic cancer. Co-author DOI 10.2174/09298673113209990196↗
  36. Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells. Co-author DOI 10.2174/09298673113209990249↗
  37. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Co-author DOI 10.2174/09298673113209990251↗
  38. Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2012.03.010↗
  39. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathw… Co-author DOI 10.1016/j.canlet.2012.02.035↗
  40. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Co-author DOI 10.2174/13816128112092395↗
  41. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Co-author DOI 10.2174/13816128112092404↗
  42. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. Co-author DOI 10.1371/journal.pone.0027074↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 37 shared papers, 2011–2020 · strength 1.82
  2. Xuqi Li · 27 shared papers, 2012–2025 · strength 1.49
  3. Wanxing Duan · 30 shared papers, 2012–2020 · strength 1.48
  4. Jiguang Ma · 23 shared papers, 2013–2020 · strength 1.24
  5. Jianjun Lei · 25 shared papers, 2012–2020 · strength 1.23
  6. Zheng Wang · 17 shared papers, 2012–2025 · strength 1.15
  7. Erxi Wu · 23 shared papers, 2011–2020 · strength 0.99
  8. Ganghua Yang · 2 shared papers, 2025 · strength 0.57
  9. Zhengdong Jiang · 10 shared papers, 2015–2018 · strength 0.52
  10. Liang Cheng · 6 shared papers, 2018–2020 · strength 0.49
  11. Wei Li · 10 shared papers, 2011–2018 · strength 0.44
  12. Weikun Qian · 5 shared papers, 2018–2020 · strength 0.44
  13. Zheng Wu · 9 shared papers, 2013–2017 · strength 0.39
  14. Liang Han · 8 shared papers, 2013–2018 · strength 0.39
  15. Liang Han · 9 shared papers, 2011–2015 · strength 0.37
  16. Liankang Sun · 5 shared papers, 2017–2020 · strength 0.37
  17. Liang Zong · 7 shared papers, 2015–2018 · strength 0.35
  18. Bin Yan · 4 shared papers, 2018–2019 · strength 0.30
  19. Zhenhua Ma · 7 shared papers, 2013–2017 · strength 0.30
  20. Shuo Zhao · 1 shared paper, 2025 · strength 0.30
  21. Tao Qin · 3 shared papers, 2019–2020 · strength 0.29
  22. Cancan Zhou · 4 shared papers, 2017–2019 · strength 0.28
  23. Ke Chen · 4 shared papers, 2016–2019 · strength 0.27
  24. Yong Wan · 1 shared paper, 2025 · strength 0.27
  25. Lun Zhang · 6 shared papers, 2013–2016 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.